Acquiring Exclusive Japanese Rights to ATYR1923 from aTyr
First written in FY2020-Q3. 2 of 8 entries say "Advanced", first in FY2021-Q2. Latest entry: 2026-07-30.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Meanwhile, following the failure to meet the primary endpoint in the global joint Phase III clinical trial for KRP-R120, a treatment for interstitial lung disease, discussions are continuing with aTyr, the licensor, regarding the future direction of the programme.」
Following the failure to meet the primary endpoint in the global joint Phase III trial of KRP-R120, discussions with the licensor regarding the future direction of the programme are continuing. - FY2026-H1WorsenedAnnual report
「For KRP-R120, a treatment for interstitial lung disease, the primary endpoint was not met in the global joint Phase III clinical trial.」
For KRP-R120, it was explicitly stated that the primary endpoint was not met in the global joint Phase III clinical trial, replacing the previous description that the trial was progressing steadily. - FY2025-H1RestatedAnnual report
「Regarding progress in domestic and overseas development during the interim consolidated accounting period, there were no transitions between clinical-trial phases, but the respective trials for KRP-R120, a treatment for interstitial lung disease, and KRP-114VP, a treatment for overactive bladder (the paediatric indication of Beova), as well as the specified clinical research study for KRP-DT123, an app for treating tinnitus, are progressing steadily.」
It was stated that the trial for in-licensed product KRP-R120 was progressing steadily, although there had been no transition to a new phase. - FY2023-Q2AdvancedAnnual report
「Kyorin Pharmaceutical Co., Ltd. also decided to conduct a global joint clinical trial with aTyr, headquartered in the United States, for KRP-R120, a treatment for interstitial lung disease (pulmonary sarcoidosis), and began a Phase III clinical trial in Japan in September of the same year.」
KRP-R120, licensed in from aTyr, progressed substantially from a Phase I clinical trial to the start of a Japan-based Phase III clinical trial as part of a global joint clinical trial. - FY2021-Q2AdvancedAnnual report
「The company also entered into a license agreement with aTyr, Inc. (headquartered in the United States) and began a Phase I clinical trial in July of the same year in healthy adult Japanese men for KRP-R120 (ATYR1923), a treatment for interstitial lung disease licensed from aTyr, Inc.」
A Phase I clinical trial was initiated for ATYR1923, for which development and marketing rights in Japan had been acquired from aTyr. - FY2020-Q3First statedAnnual report
「In January 2020, KYORIN Pharmaceutical Co.,Ltd. entered into a license agreement with aTyr for the novel immunomodulator ATYR1923 and acquired exclusive rights to develop and market the product in Japan for interstitial lung disease.」
Exclusive development and marketing rights in Japan for ATYR1923 were acquired from aTyr.